| Title | Venue | Year | Impact | Source |
| 6101 | POS-893 CHRONIC KIDNEY DISEASE IN PATIENTS WITH COVID-19: A DESCRIPTIVE ANALYSIS | Kidney Int Rep | 2022 | | CORD-19 |
| 6102 | POS-894 PREDICTING PANDEMIC-RELATED EXCESS-DEATH USING PRE-PANDEMIC RISK OF MORTALITY IN INDIVIDUALS WITH CHRONIC KIDNEY DISEASE Introduction: Chronic Kidney Disease (CKD) is a global burden on public health, both as a risk factor for mortality, and as the end syndrome of underlying diseases. CKD is a common comorbidity associated with increased risk of severe coronavirus infection and poor clinical outcomes. The pandemic has had both direct (through infection) and indirect impact. The direct impact on individuals with CKD and other underlying conditions is related to baseline risk, influenced by age, multimorbidity and other socio-demographic factors. However, previous studies of COVID-19 in CKD have been small scale (12-1099 cases), mostly focused on end-stage CKD, and ignored major comorbidities. Thus, using large-scale, population-based electronic health records, in people with incident CKD we aimed to (a) identify the most common comorbidities;(b) estimate 1-year (pre-pandemic) risk of mortality and (c) predict excess deaths related to COVID-19 over 1-year of pandemic based on pre-pandemic risk of mortality at different population infection rates and relative risks. Methods: We used linked primary and secondary care records (Clinical Practice Research Datalink GOLD data) from England;of 3,862,012 individuals aged ≥ 30 registered with a GP practice between 1997 and 2017. Incident CKD was identified based on diagnosis codes and eGFR levels;classified mutually exclusively into five CKD Stages. The underlying conditions were obtained using validated phenotyping algorithms in CALIBER and the most prevalent ones were identified. The 1-year mortality were estimated using Kaplan–Meier survival analysis;stratified by key demographic factors and number of comorbidities. Using these pre-pandemic risk estimates and our recently published Lancet model, we calculated excess COVID-19 related deaths at different population infection rates and relative risks. For validation, we identified the number of people who died with both CKD and positive COVID-19 test result during 1-year of pandemic using the contemporary NHSD TRE data of England (NHS Digital Trusted Research Environment, n=54 million). Results: We identified 294,381 individuals with incident CKD (mean age 72.5 years;female: 59%). Multimorbidity was common among CKD patients especially the presence of hypertension (61.4%) and CVD complications (35.6%) (Fig 1 ). The proportion of CKD patients having at least one underlying condition increases significantly either by age or CKD stage whilst age was the main confounder within each CKD stage. Age, Stage of CKD and underlying conditions combined to influence pre-pandemic risk (Fig 2 ). At an IR of 10%, we predicted 31003 and 46505 excess deaths at RR of 2 and 3 respectively (Table 1 ) which is close to actual observed mortality (47214) from the NHSD TREin England. [Formula presented] [Formula presented] [Formula presented] Conclusions: Individuals with CKD have high risk of pre-pandemic mortality particularly those with comorbidities. The data on multimorbidity, CKD stage and age together could help prioritise patients for vaccination, post-COVID policy, and designing stratified pathways for CKD patients. We illustrate that the direct burden of pandemic could be predicted using pre-pandemic large scale EHR data. Conflict of interest Potential conflict of interest: This study was funded by AstraZeneca and Health Data Research UK. AB has received research grants from AstraZeneca. JBM and TM are employed full-time by AstraZeneca UK Ltd, a biopharmaceutical company who develops, manufactures and markets medicines in the cardiovascular, renal and metabolic disease area. | Kidney Int Rep | 2022 | | CORD-19 |
| 6103 | POS-921 CORRELATION OF NEUTROPHIL TO LYMPHOCYTE RATIO AND D-DIMER AS THROMBOSIS PREDICTOR ON REGULAR HAEMODIALYSIS PATIENT WITH COVID-19 | Kidney Int Rep | 2022 | | CORD-19 |
| 6104 | POS-686 OVERVIEW OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS PROGRAM AMONG END RENAL DISEASE PATIENTS DURING CORONA VIRUS DISEASE 2019 PANDEMIC. A SINGLE CENTRE EXPERIENCE | Kidney Int Rep | 2022 | | CORD-19 |
| 6105 | POS-874 DEATH AND KIDNEY DISEASE: IS COVID-19 COLOR-BLIND? | Kidney Int Rep | 2022 | | CORD-19 |
| 6106 | POS-866 Urinary mitochondrial DNA a new biomarkers of acute kidney injury in renal allograft recipient patients after post covid recovery | Kidney Int Rep | 2022 | | CORD-19 |
| 6107 | POS-896 QUALITY OF LIFE OF FAMILY CAREGIVERS OF PATIENTS UNDERGOING IN-CENTER HEMODIALYSIS DURING THE COVID-19 PANDEMIC: PRELIMINARY RESULTS | Kidney Int Rep | 2022 | | CORD-19 |
| 6108 | POS-933 LOW DOSE COLCHICINE PROPHYLAXIS FOR SEVERE COVID-19 PREVENTION IN PATIENTS ON HEMODIALYSIS | Kidney Int Rep | 2022 | | CORD-19 |
| 6109 | POS-938 TREATING END-STAGE RENAL DISEASE PATIENTS IN CENTER-BASED HEMODIALYSIS DURING COVID-19 PANDEMIC: WHAT (ADDITIONAL) CHALLENGES TO HEALTHCARE PROFESSIONALS? | Kidney Int Rep | 2022 | | CORD-19 |
| 6110 | POS-909 COVID-19 EVOLUTION THROUGH THREE WAVES IN THE DIAYSIS UNIT AT STEVE BIKO ACADEMIC HOSPITAL, PRETORIA, SOUTH AFRICA | Kidney Int Rep | 2022 | | CORD-19 |
| 6111 | POS-916 MORTALITY RATE AND ASSOCIATED RISK FACTORS IN HOSPITALISED COVID-19 PATIENTS WITH KIDNEY DISEASE | Kidney Int Rep | 2022 | | CORD-19 |
| 6112 | POS-858 IMPACT OF ACUTE KIDNEY DISEASE ON MORTALITY OF HOSPITALIZED COVID-19 PATIENTS | Kidney Int Rep | 2022 | | CORD-19 |
| 6113 | POS-890 SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS SYNDROME REVEALING PLASMA-CELL LEUKEMIA IN A COVID-19 PATIENT PRESENTING WITH KIDNEY INJURY | Kidney Int Rep | 2022 | | CORD-19 |
| 6114 | POS-879 PREVALENCE OF SARS-CoV-2 INFECTION IN RENAL TRANSPLANT RECIPIENTS- A RETROSPECTIVE STUDY | Kidney Int Rep | 2022 | | CORD-19 |
| 6115 | POS-931 THE IMPACT OF COVID-19 PANDEMIC ON SURVIVAL OF IN-CENTRE MAINTENANCE HAEMODIALYSIS PATIENTS OF A COVID-19 DESIGNATED HOSPITAL IN MALAYSIA | Kidney Int Rep | 2022 | | CORD-19 |
| 6116 | POS-878 Peritoneal Dialysis during COVID-19 pandemic. A report from a third level center from Mexico. The COVMEX-PD Cohort | Kidney Int Rep | 2022 | | CORD-19 |
| 6117 | POS-930 ANCA ASSOCIATED VASCULITIS WITH CRESCENTIC GLOMERULONEPHRITIS COMPLICATING COVID-19 IN A 72-YEAR-OLD MAN | Kidney Int Rep | 2022 | | CORD-19 |
| 6118 | POS-766 A RARE ASSOCIATION: PHLEGMASIA CERULEA DOLENS AND SARS COV 2 INFECTION IN A KIDNEY TRANSPLANT RECIPIENT | Kidney Int Rep | 2022 | | CORD-19 |
| 6119 | POS-959 CLINICAL PROFILE AND OUTCOME OF SARS-CoV-2 INFECTION IN RENAL TRANSPLANT RECIPIENTS-A SINGLE CENTRE EXPERIENCE | Kidney Int Rep | 2022 | | CORD-19 |
| 6120 | POS-971 RECURRING COVID-19 IN PATIENT WITH END STAGE RENAL DISEASE-A CASE OF PROBABLE REINFECTION | Kidney Int Rep | 2022 | | CORD-19 |
| 6121 | POS-990 PODOCYTES TO PODCASTS: NEW AVENUES FOR VIRTUAL NEPHROLOGY LEARNING DURING COVID-19 | Kidney Int Rep | 2022 | | CORD-19 |
| 6122 | POS-969 IMPACT OF VACCINATION ON CLINICAL OUTCOME OF HOSPITALISED END STAGE KIDNEY DISEASE PATIENTS WITH COVID-19 INFECTION. A SINGLE CENTRE EXPERIENCE | Kidney Int Rep | 2022 | | CORD-19 |
| 6123 | POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS | Kidney Int Rep | 2022 | | CORD-19 |
| 6124 | POS-763 OUTCOME OF ABO-INCOMPATIBLE KIDNEY TRANSPLANTATIONS DURING COVID-19 PANDEMIC: A SINGLE CENTRE EXPERIENCE | Kidney Int Rep | 2022 | | CORD-19 |
| 6125 | POS-685 SARS-COV2 INFECTION IN PATIENTS ON PERITONEAL DIALYSIS | Kidney Int Rep | 2022 | | CORD-19 |
| 6126 | POS-885 CLINICAL CHARACTERISTICS AND OUTCOME OF HOSPITALIZED COVID-19 PATIENTS WITH KIDNEY DISEASE IN A TERTIARY CENTRE | Kidney Int Rep | 2022 | | CORD-19 |
| 6127 | POS-861 INCIDENCE AND RISK FACTORS OF ACUTE KIDNEY INJURY WITH SARS-CoV-2 INFECTION IN DISADVANTAGED POPULATION | Kidney Int Rep | 2022 | | CORD-19 |
| 6128 | POS-911 IMPACT OF CHRONIC RAAS INHIBITORS USE IN ELDERLY COVID PATIENTS: A RETROSPECTIVE ANALYSIS | Kidney Int Rep | 2022 | | CORD-19 |
| 6129 | POS-919 OUTCOMES OF HEMODIALYSIS PATIENTS WITH COVID-19 IN A SINGLE DIALYSIS CENTER AT A TERTIARY CARE HOSPITAL OVER A PERIOD OF 1 YEAR | Kidney Int Rep | 2022 | | CORD-19 |
| 6130 | POS-934 ATYPICAL MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) PRESENTING AS GROSS ASCITES IN A CHILD WITH END STAGE KIDNEY DISEASE Introduction: Mankind has been ravaged by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since 2019. To date, we are still battling with coronavirus disease 2019 (COVID19). Although children seem to experience milder symptoms with acute COVID19 illness, some are burdened by multisystem inflammatory syndrome in children (MIS-C) that classically observes a temporal relationship with COVID19. Methods: Clinical data retrieved from medical records and hospital electronic database with permission. Results: We report herein a 7-year-old incident dialysis patient with an atypical presentation of MIS-C. He had previously experienced recurrent peritoneal dialysis-related peritonitis, which resulted in the removal of his tenckhoff catheter and was subsequently on chronic hemodialysis. He developed COVID-19 pneumonia after adults in the family caught the infection. The child experienced an uneventful recovery with nasal oxygen supplementation and a course of steroids. However, he developed gross abdominal distension approximately three weeks post COVID-19 which was not associated with fever or abdominal tenderness. A bedside ultrasound of the lungs suggested a normohydrated state with no signs of increased extravascular lung water. Simple ascites was demonstrated on ultrasound of the abdomen with a serum-ascites albumin gradient (SAAG) of less than 1.1g/dL and an ascitic protein of 48g/L. The sample had a normal fluid cytology and was negative for bacterial, fungal and mycobacterial cultures. Interestingly, our patient had remarkably high inflammatory markers ie C-Reactive Protein (CRP) 111 mg/L, Procalcitonin 7.47 ng/mL, D-Dimer >7.65 mcg/mL and Ferritin 1650 mcg/L despite the absence of fever. The liver enzymes and complete blood counts were unremarkable apart from transient reactive thrombocytosis. His echocardiogram showed minimal pericardial effusion and the absence of coronary arteries dilatation. In the light of his complex clinical presentation, temporal relation with recent COVID-19 and unexplained signs of hyperinflammation, he was treated with Intravenous Immunoglobulin 2g/kg. Following that, we observed steady improvement of the inflammatory markers and resolution of the reactive ascites. At the time of writing, six weeks lapsed and he remained well on chronic hemodialysis. Conclusions: In conclusion, the exorbitantly high inflammatory markers and gross ascites otherwise unexplained by another disease proess could reflect an immune dysregulation post COVID-19 or an atypical presentation of MIS-C. Much is yet to be known of this very complex disease in children. No conflict of interest | Kidney Int Rep | 2022 | | CORD-19 |
| 6131 | POS-912 EFFECTIVENESS OF SARS-COV 2 VACCINATION IN KIDNEY TRANSPLANT PATIENTS IN CHILE | Kidney Int Rep | 2022 | | CORD-19 |
| 6132 | POS-900 STUDY OF CLINICAL SPECTRUM AND OUTCOMES OF COVID RELATED MUCORMYCOSIS IN PATIENTS WITH RENAL INSUFFICIENCY | Kidney Int Rep | 2022 | | CORD-19 |
| 6133 | POS-913 COVID-19 INCIDENCE AND OUTCOMES IN PERITONEAL DIALYSIS UNIT IN SFAX (TUNISIA) AT THE HEIGHT OF THE PANDEMIC | Kidney Int Rep | 2022 | | CORD-19 |
| 6134 | POS-905 PROSPECTIVE STUDY ON COVID-19 INFECTION IN KIDNEY TRANSPLANT RECIPIENTS IN SABAH: A PRELIMINARY RESULT | Kidney Int Rep | 2022 | | CORD-19 |
| 6135 | POS-870 NGAL and microalbuminuria as AKi biomarkers in COVID-19 hospitalized patients with pneumonia | Kidney Int Rep | 2022 | | CORD-19 |
| 6136 | POS-940 ANTIBODY RESPONSE TO PFIZER BNT162b2 VACCINE IN HEMODIALYSIS PATIENTS: THE PREVIOUS SARS-CoV-2 INFECTION INFLUENCE | Kidney Int Rep | 2022 | | CORD-19 |
| 6137 | POS-932 INCIDENCE AND OUTCOMES OF COVID-19 INFECTION AMONG IN-CENTRE MAINTENANCE HAEMODIALYSIS (HD) PATIENTS IN A TERTIARY HOSPITAL IN MALAYSIA | Kidney Int Rep | 2022 | | CORD-19 |
| 6138 | POS-580 BURDEN OF COVID-19 IN A HEMODIALYSIS CENTER IN SUB-SAHARAN AFRICA | Kidney Int Rep | 2022 | | CORD-19 |
| 6139 | POS-915 DETERMINANTS OF MORTALITY OF COVID-19 INFECTION IN HEMODIALYSIS PATIETS: DATA FROM A TERTIARY CARE INSTITUTE IN SOUTH INDIA | Kidney Int Rep | 2022 | | CORD-19 |
| 6140 | POS-889 HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS SECONDARY TO COVID-19 IN PATIENTS WITH CHRONIC KIDNEY DISEASE: WHEN WORSE COMES TO WORST | Kidney Int Rep | 2022 | | CORD-19 |
| 6141 | POS-899 RISKS ASSOCIATED WITH DEATH IN COVID-19 PATIENTS WHO UNDERWENT HEMODIALYSIS: AN EXPERIENCE IN COVID-19 REFERRAL HOSPITAL | Kidney Int Rep | 2022 | | CORD-19 |
| 6142 | POS-865 RENAL RECOVERY AFTER ACUTE KIDNEY INJURY ASSOCIATED TO COVID REQUIRING CONTINUOUS RENAL REPLACEMENT THERAPY DURING ICU HOSPITALIZATION | Kidney Int Rep | 2022 | | CORD-19 |
| 6143 | POS-907 COVID-19 AND SARS-CoV-2 VACCINE IN HEMODIALYSIS PATIENTS. EXPERIENCE IN A GUATEMALAN CENTER | Kidney Int Rep | 2022 | | CORD-19 |
| 6144 | POS-881 EXTRACORPOREAL BLOOD PURIFICATION TREATMENT IN COVID-19 PATIENTS WITH ACUTE KIDNEY INJURY | Kidney Int Rep | 2022 | | CORD-19 |
| 6145 | POS-928 EFFICACY OF THE PFIZER/ BNT162b2 COVID-19 VACCINE IN PERITONEAL DIALYSIS PATIENTS | Kidney Int Rep | 2022 | | CORD-19 |
| 6146 | POS-926 IN-CENTRE HAEMODIALYSIS CENTRES VARIABLY AFFECTED BY THE CORONAVIRUS-2019 PANDEMIC IN DIFFERENT REGIONS OF THE WORLD: THE INTERNATIONAL SOCIETY OF NEPHROLOGY-DIALYSIS OUTCOMES PRACTICE PATTERNS STUDY SURVEY | Kidney Int Rep | 2022 | | CORD-19 |
| 6147 | POS-902 INTRAUTERINE FETAL DEATH IN PREGNANT WOMAN ON CHRONIC DIALYSIS WITH SARS-COV-2 INFECTION: A CASE REPORT | Kidney Int Rep | 2022 | | CORD-19 |
| 6148 | POS-888 COVID-19 PATIENTS WITH A NEPHROLOGIC CONCERN: A DESCRIPTIVE STUDY FROM A SINGLE CENTER IN TUNISIA | Kidney Int Rep | 2022 | | CORD-19 |
| 6149 | POS-855 MORTALITY RATE AND ACUTE KIDNEY INJURY PREVALENCE REDUCTION IN COVID-19 CRITICAL PATIENTS TREATED WITH HEMOPERFUSION | Kidney Int Rep | 2022 | | CORD-19 |
| 6150 | POS-904 OUTCOMES OF COVID-19 IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SCOTTISH OBSERVATIONAL STUDY | Kidney Int Rep | 2022 | | CORD-19 |
